Biotech Firm Immunic Faces Mixed Analyst Opinions Immunic, Inc. (NASDAQ: IMUX) continues to attract diverse analyst ratings. While H.C. Wainwright maintains a 'Buy' rating with a $10 price target, other analysts express concerns over cash burn and market volatility. The firm awaits key trial results for its lead candidate, vidofludimus calcium, expected in April.2